Lilly Reports Results of Lebrikizumab in P-III ADvocate 1 and 2 Studies for the Treatment of Moderate to Severe Atopic Dermatitis

Shots:

• The ongoing P-III ADvocate 1 & 2 studies evaluate lebrikizumab as monothx. vs PBO in adult & adolescent patients aged 12 to less than 18 yrs. with mod. to sev. AD for 52wks.
• The 1EPs & 2EPs of study i.e >75% change from baseline in EASI score @16wks., improvement in skin clearance & itch including QoL while safety profile was consistent with prior studies of lebrikizumab
• Lilly gets exclusive rights for the development & commercialization of lebrikizumab in the US & other countries outside the EU while Almirall gets the rights to develop and commercialize the therapy for dermatology indications including the AD in the EU. The therapy has received FTD for a mod. to sev. AD

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Wall Street Journal